PA
CERE

Perceptive Advisors’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Perceptive Advisors’s Portfolio CERE Stock Details CERE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-10,794,876
Closed -$441M – 127
2024
Q2 		$441M Hold
10,794,876
– – 10.63% 1
2024
Q1 		$456M Sell
10,794,876
-170,317
-2% -$7.15M 7.98% 1
2023
Q4 		$465M Buy
10,965,193
+876,808
+9% +$25.2M 10.38% 1
2023
Q3 		$220M Hold
10,088,385
– – 7.35% 2
2023
Q2 		$321M Buy
10,088,385
+3,576,658
+55% +$110M 9.28% 2
2023
Q1 		$159M Hold
6,511,727
– – 4.69% 4
2022
Q4 		$205M Hold
6,511,727
– – 5.77% 4
2022
Q3 		$184M Buy
6,511,727
+1,425,000
+28% +$42.4M 5.34% 3
2022
Q2 		$134M Hold
5,086,727
– – 4.21% 4
2022
Q1 		$178M Hold
5,086,727
– – 3.57% 8
2021
Q4 		$165M Hold
5,086,727
– – 2.54% 10
2021
Q3 		$150M Buy
5,086,727
+443,632
+10% +$12.5M 2.18% 11
2021
Q2 		$119M Hold
4,643,095
– – 1.54% 18
2021
Q1 		$63.7M Buy
4,643,095
+99,033
+2% +$1.45M 0.81% 32
2020
Q4 		$75.3M Buy
+4,544,062
New +$59M 0.81% 35

Other funds holding CERE

IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return

Perceptive Advisors's CERE Position: Q3 2024 in Review

Perceptive Advisors sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q3 2024, closing a stake of 10,794,876 shares — an estimated $441M sold.

Perceptive Advisors first reported a position in CERE in Q4 2020 and held it in 15 quarters. The position peaked at $465M in Q4 2023. 2 funds tracked by Wall St. Rank hold CERE as of Q3 2024.

  • Perceptive Advisors reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • Perceptive Advisors sold 10,794,876 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q3 2024, an estimated $441M.
  • Perceptive Advisors first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q4 2020 and held it in 15 quarters.
  • Perceptive Advisors's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $465M in Q4 2023.
  • 2 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q3 2024.

Based on Perceptive Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.